Adial Pharmaceuticals filings document the regulatory record of a Nasdaq-listed, clinical-stage biopharmaceutical company developing AD04 for alcohol use disorder and related addiction indications. Its Form 8-K filings include financial-result releases, Regulation FD disclosures on AD04 commercialization frameworks, Nasdaq compliance notices, certificate and securityholder-rights matters, and governance updates.
Proxy and governance filings describe stockholder voting matters, including warrant-related share issuance approvals under Nasdaq rules, board matters, and equity-incentive compensation. The filing record also covers restricted stock awards, director changes, private-placement warrant mechanics, common stock capital structure, and public-company disclosure controls relevant to Adial’s development-stage operating model.
Adial Pharmaceuticals, Inc. amended its second-quarter report to restate certain sections after SEC staff comments and incorporate subsequent transaction amendments. It completed the June 11, 2026 acquisition of Azora Therapeutics, shifting its lead program to AT177 for ulcerative colitis; the June 12, 2026 initial private-placement closing produced approximately $24.3 million in net proceeds. For the six months ended June 30, 2026, net loss was $54.012 million versus $4.188 million a year earlier, including $46.185 million of acquired in-process research and development expense; cash and equivalents were $28.712 million at June 30, 2026.
Management reported substantial doubt about continued operations, assuming Series A preferred-stock cash-settlement obligations are triggered. If Adial fails to timely deliver common shares upon conversion, holders may require cash equal to the fair value of undelivered shares after the earlier of stockholder approval or December 11, 2026. September amendments removed warrant-purchase penalty provisions and added transfer restrictions, subject to exceptions, on certain shares; they also changed milestone warrant rights to equity classification. Adial plans to submit an IND for AT177 in the first half of 2027 and, subject to regulatory agencies allowing studies to proceed, begin Phase 1a followed by Phase 1b studies.
Adial Pharmaceuticals, Inc. is registering up to 25,148,970 common shares for resale by selling stockholders; they may not sell until the registration statement is effective. The total includes 437,421 merger shares, 12,930,601 shares issuable upon conversion of Series A preferred stock, and warrant shares for 9,749,345 and 2,031,603 common shares. Adial will receive no resale proceeds; it would receive the nominal $0.001 exercise price if the pre-funded warrants are exercised for cash.
Adial acquired Azora on June 11, 2026, adding AT177, a candidate for ulcerative colitis now in IND-enabling studies. An IND filing and Phase 1a trial are planned for the first half of 2027, subject to regulatory authorities allowing them to proceed. The June PIPE generated approximately $24.3 million in net proceeds.
Stockholder approval of the preferred conversion and Nasdaq’s conditional listing approval are pending; the related meeting was adjourned to October 26, 2026. If approval is not obtained by December 11, 2026, holders submitting conversion notices could require cash settlement. At the September 30 closing price of $4.01, settlement of all conversion shares was estimated at approximately $51.9 million; cash and equivalents were approximately $28.7 million as of June 30, 2026.
Adial Pharmaceuticals, Inc. further adjourned its 2026 Annual Meeting vote on Proposals 3, 4, 5 and 6 because it had not received Nasdaq approval of the Initial Listing Application. The polls remain open, and the proposals have not changed.
The meeting will reconvene on October 26, 2026, at 8:30 a.m. Eastern Time in Charlottesville, Virginia. The record date remains August 17, 2026. Stockholders who already submitted proxies voting on Proposals 3, 4, 5 and 6 need take no further action unless they wish to change their vote.
Adial Pharmaceuticals, Inc. further adjourned the 2026 Annual Meeting votes on Proposals 3, 4, 5 and 6 because it still had not received Nasdaq’s approval of its Initial Listing Application. The meeting reconvened on October 1, 2026, for those proposals before being adjourned again.
The meeting is scheduled to reconvene October 15, 2026, at 8:30 a.m. Eastern Time, and the polls remain open. Votes on Proposals 1, 2, 7, 8, 9, 10, 11 and 12 had already been held. The record date remains August 17, 2026. Stockholders who submitted proxies on Proposals 3, 4, 5 and 6 need not take further action unless they wish to change their votes.
ADIAL PHARMACEUTICALS, INC. (ADIL) reported that director Wendy B. Young received a grant of stock options for 25,666 shares of common stock on June 12, 2026, at an exercise price of $2.98 per share, expiring June 12, 2036.
The board approved this grant on June 11, 2026, subject to stockholder approval of an increase to the 2017 Equity Incentive Plan, which stockholders provided on September 17, 2026. 2,138 options vested on that approval date, with the remaining 23,528 options vesting in substantially equal installments over 33 months beginning October 12, 2026. No Rule 10b5-1 plan is reported.
Adial Pharmaceuticals, Inc. (ADIL) reported results from its 2026 Annual Meeting of Stockholders held on September 17, 2026. Stockholders approved Amendment No. 8 to the 2017 Equity Incentive Plan, a new 2026 Equity Incentive Plan, and a 2026 Employee Stock Purchase Plan, expanding the company’s ability to grant equity-based compensation. They also approved an amendment to the certificate of incorporation increasing authorized common shares from 100,000,000 to 500,000,000, and approved the potential issuance of up to 552,940 shares upon exercise of Series F warrants to comply with Nasdaq Listing Rule 5635(d). An adjournment proposal was approved, and the meeting was partially adjourned with respect to four other proposals tied to Nasdaq approvals; those proposals will be voted when the meeting reconvenes on October 1, 2026.
Adial Pharmaceuticals, Inc. (ADIL) amended its June 11, 2026 Securities Purchase Agreement and Note Exchange Agreements to remove a “Penalty Provision” tied to Milestone Warrants and add lock-up restrictions on certain shares issuable from pre-funded warrants. This change allows the Milestone Warrant rights to be reclassified from a liability to equity.
Pro forma as of June 30, 2026, reclassifying $22.7 million of Milestone warrant rights from liability to additional paid-in capital and converting all 12,930.617 Series A Non-Voting Convertible Preferred shares (previously $38.5 million in temporary equity) into common stock turns stockholders’ equity from a $38.4 million deficit to positive $22.9 million, with common shares increasing from 2,625,890 to 15,556,507.
The company states that these steps are intended to help regain compliance with Nasdaq Capital Market continued listing requirements and satisfy initial listing standards in connection with an anticipated change of control, which depends on stockholder approval of the conversion of the Series A Preferred Stock at the 2026 Annual Meeting.
Adial Pharmaceuticals, Inc. (ADIL) has filed an S-3 registration statement covering the potential resale of up to 25,148,970 shares of Common Stock by existing security holders. These Resale Shares comprise 437,421 Merger Common Shares, 12,930,601 Merger Conversion Shares from Series A Non-Voting Convertible Preferred Stock, and 11,780,948 shares issuable upon exercise of pre-funded warrants issued in the PIPE financing and Azora note exchange.
The shares were originally issued in connection with Adial’s June 11, 2026 acquisition of Azora Therapeutics and a June 12, 2026 PIPE that generated approximately $24.3 million in net proceeds, alongside the retirement of $5.5 million of Azora notes via Noteholder Pre-Funded Warrants. Adial will not receive proceeds from resale of the registered shares, other than a nominal $0.001 per share upon any cash warrant exercises. Common Stock outstanding after this offering is stated as 27,337,439 shares, and the stock last traded at $5.94 on August 26, 2026.
Adial Pharmaceuticals, Inc. (ADIL) reported granting a stock option as a material inducement for a new employee to join the company. On August 19, 2026, the company granted an option to purchase 307,814 shares of common stock at an exercise price of $5.76 per share, the closing price on the grant date. The option has a ten-year term and will vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments thereafter, subject to continued service. The grant was made outside the company’s equity incentive plans under the employment inducement exception in Nasdaq Listing Rule 5635(c)(4) and relies on an exemption from registration under Section 4(a)(2) of the Securities Act and Regulation D. The option and underlying shares may not be sold in the United States without registration or an applicable exemption.